Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

• Main Authors: Linda Davidson (Author), Juul M.P.A. van den Reek (Author), Mariolina Bruno (Author), Florence van Hunsel (Author), Ron M.C. Herings (Author), Vasiliki Matzaraki (Author), Collins K. Boahen (Author), Vinod Kumar (Author), Hans M.M. Groenewoud (Author), Frank L. van de Veerdonk (Author), Mihai G. Netea (Author), Elke M.G.J. de Jong (Author), Bart Jan Kullberg (Author)
• Format: Book
• Published: Elsevier, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Biologics directed against the T-helper (Th)-17 pathway have been approved for several inflammatory diseases. Interleukin (IL)-17 is involved in anti-Candida host defense, and clinical trials suggested increased candidiasis incidence during IL-17 inhibitor therapy. We describe t...